Elaine Mary Shannon net worth and biography

Elaine Shannon Biography and Net Worth

President, Global Supply & Quality of Takeda Pharmaceutical

Elaine Shannon is the president of Global Supply & Quality, where she leads internal and external manufacturing, supply chain and quality activities across the company’s manufacturing network to ensure uninterrupted and sustainable supply of Takeda’s product portfolio.

Most recently, Elaine served as global quality officer from 2023 to 2026, where she oversaw the quality organization, embedding a consistent, enterprise quality management system as well as strengthening a culture of quality. In that role, Elaine also initiated a transformation of the global quality organization, including a new operating model and capabilities.

Elaine has held roles of increasing responsibility at Takeda, where she has honed her expertise in quality, manufacturing, and oncology. Likewise, she has served as head for Takeda’s Massachusetts Biologics Operations manufacturing site, as well as global head of quality oncology & external supply small molecules and global head of quality audits and supplier management. She joined Takeda’s global quality compliance and systems group in June 2016 to develop the company’s knowledge management processes.

Elaine has 25 years of industry experience in quality, compliance, quality assurance and R&D, including work with Teva Pharmaceuticals and Pinewood Healthcare.

Outside of Takeda, Elaine is involved in industry and community leadership through her membership in the Parenteral Drug Association (PDA) and her service on the Board of Directors of Associated Industries of Massachusetts (AIM).

She holds a master’s degree in pharmaceutical manufacturing technology and a bachelor’s degree in good manufacturing practices (GMP).

Elaine lives in the Boston area with her husband and two children.

What is Elaine Mary Shannon's net worth?: The estimated net worth of Elaine Mary Shannon is at least $1.10 million as of August 10th, 2026. Ms. Shannon owns 63,333 shares of Takeda Pharmaceutical stock worth more than $1,103,261 as of August 13th. This net worth estimate does not reflect any other assets that Ms. Shannon may own. Learn More about Elaine Mary Shannon's net worth.
How do I contact Elaine Mary Shannon?: The corporate mailing address for Ms. Shannon and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Elaine Mary Shannon's contact information.
Has Elaine Mary Shannon been buying or selling shares of Takeda Pharmaceutical?: In the last ninety days, Elaine Mary Shannon has sold $68,023.80 of Takeda Pharmaceutical stock. Most recently, Elaine Mary Shannon sold 3,978 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $68,023.80. Following the completion of the sale, the insider now directly owns 63,333 shares of the company's stock, valued at $1,082,994.30. Learn More on Elaine Mary Shannon's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Julie Kim (Representative Director – President and CEO), Giles Platford (President, International Business Unit), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 444,100 shares worth more than $7,594,110.00. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Elaine Mary Shannon Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	3,978	$17.10	$68,023.80	63,333

Elaine Mary Shannon Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.38

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

378,150 shs

Average Volume

3,167,810 shs

Market Capitalization

$55.80 billion

P/E Ratio

51.22

Dividend Yield

2.75%

Beta

N/A